The vaccine is manufactured at Valneva’s leading vaccine production site in Livingston, Scotland. The approval is based on IXCHIQ®’s final pivotal Phase 3 data, published in The Lancet ...

Robert F. Kennedy Jr. spent the first day of his back-to-back confirmation hearings deftly avoiding questions about his views on vaccines. On the second day, when a prominent Republican senator ...

for the world’s first and only chikungunya vaccine, IXCHIQ ®. The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV ...

The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years and older, but Bavarian Nordic’s Vimkunya is the first chikungunya vaccine ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing chikungunya disease in adults only, although, it is in clinical ...

The agency approved the company's chikungunya vaccine, Ixchiq, for use in people 18 years of age and older. Late-stage trial data show the vaccine "induces a rapid and strong immune response ...

The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in LimmaTech's ...

Having an edge over competitors in the market place by having a superior product, as well as promoting it and distributing it more effectively. Gaining a competitive edge may be a result of correctly ...